MARKET

XOMA

XOMA

XOMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.53
-1.82
-8.94%
Closed 16:00 04/01 EDT
OPEN
19.77
PREV CLOSE
20.35
HIGH
20.23
LOW
17.78
VOLUME
43.22K
TURNOVER
--
52 WEEK HIGH
28.85
52 WEEK LOW
11.58
MARKET CAP
180.89M
P/E (TTM)
-75.4786
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average XOMA stock price target is 46.33 with a high estimate of 80.00 and a low estimate of 29.00.

EPS

XOMA News

More
  • Can You Imagine How Chuffed XOMA's (NASDAQ:XOMA) Shareholders Feel About Its 215% Share Price Gain?
  • Simply Wall St. · 03/13 15:53
  • XOMA EPS misses by $0.21, misses on revenue
  • seekingalpha · 03/10 16:35
  • XOMA Reports Fourth Quarter and Full-Year 2019 Financial Results and Operating Highlights
  • GlobeNewswire · 03/10 12:30
  • XOMA Q4 EPS $(0.49) Down From $(0.35) YoY, Sales $423K Down From $1.685M YoY
  • Benzinga · 03/10 11:39

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About XOMA

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.
More

Webull offers kinds of XOMA Corp stock information, including NASDAQ:XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions.